ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT

NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues investigating potential securities claims on behalf of shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) resulting from allegations that Sarepta may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Sarepta […]

NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues investigating potential securities claims on behalf of shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) resulting from allegations that Sarepta may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Sarepta securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=1306 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

WHAT IS THIS ABOUT: On March 16, 2023, after market hours, the Company issued a press release which “announced that at its late cycle meeting for the SRP-9001 (delandistrogene moxeparvovec) biologics license application (BLA), the U.S. Food and Drug Administration’s Office of Therapeutics (OTP) has determined that an advisory committee meeting will be held for SRP-9001 in advance of the May 29, 2023 regulatory action date.”

As explained by the Investor’s Business Daily in an article entitled “Sarepta Crashes on an Unexpected Roadblock for Its Gene Therapy”, the Food and Drug Administration’s decision was a surprise. The article quoted a UBS analyst as saying that “given the announcement of the advisory committee decision, against a backdrop of the Office of Therapeutics communicating how capacity constrained it is at every public appearance, we do see a potential risk of (approval date) extension.”

On this news, the price of Sarepta’s stock fell $26.98, or 18%, to close at $122.69 per share on March 17, 2023, the next trading day.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8802257

Total
0
Shares
Previous Article

ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT

Next Article

ROSEN, LEADING INVESTOR COUNSEL, Encourages adidas AG Investors to Inquire About Securities Class Action Investigation – ADDYY, ADDDF

Related Posts

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Eargo, Inc. Investors with Losses Over $100K to Secure Counsel Before Important December 6 Deadline in Securities Class Action – EAR

NEW YORK, Nov. 05, 2021 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Eargo, Inc. (NASDAQ: EAR) between February 25, 2021 and September 22, 2021, inclusive (the “Class Period”), of the important December 6, 2021 lead plaintiff deadline. SO WHAT: If you purchased Eargo […]

New Partnership In The Hospitality Sector In Gabon

LIBREVILLE, GABON – African Media Agency – 3 August 2023 – The Fonds Gabonais d’Investissements Stratégiques (FGIS), its subsidiaries Façade Maritime du Champ Triomphal (FMCT), an urban development company, Luxury Green Resorts (LGR), a Gabonese tourism operator, on one hand, and the Kasada group, on the other hand, signed a partnership agreement on August 2nd, […]

Torq Advancing Discoveries in 2024

VANCOUVER, BC / ACCESSWIRE / January 18, 2024 / Torq Resources Inc. (TSX-V:TORQ)(OTCQX:TRBMF) ("Torq" or the "Company") is pleased to provide a summary of key activities and achievements over the past calendar year and look ahead at...